Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28605598 | 0.78 | KMT2A (1.00) | KMT2AMEN1KDM4ELMNAHPGD | |
| SCHEMBL11285417 | 0.75 | KMT2A (0.70) | KMT2AMEN1KDM4ELMNAHPGD | |
| SCHEMBL5353705 | 0.74 | KMT2A (0.81) | KMT2AMEN1KDM4ELMNAHPGD | |
| SCHEMBL2985102 | 0.74 | KMT2A (0.64) | KMT2AMEN1KDM4ELMNAHPGD | |
| SCHEMBL10079871 | 0.73 | ALDH1A1 (0.72) | KMT2AMEN1KDM4ELMNAHPGD | |
| SCHEMBL14520097 | 0.73 | MEN1 (0.66) | KMT2AMEN1KDM4ELMNAHPGD | |
| SCHEMBL2983809 | 0.73 | PTGER4 (0.45) | KDM4ELMNAPTGER4POLBGAA | |
| SCHEMBL3712296 | 0.72 | MAPK10 (0.76) | KMT2AMEN1KDM4ELMNAHPGD | |
| SCHEMBL1947868 | 0.70 | ALDH1A1 (0.68) | KMT2AMEN1KDM4ELMNAHPGD | |
| SCHEMBL28605594 | 0.70 | MAPK8 (1.00) | KMT2AMEN1KDM4ELMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | claimed |
| CN-1551866-A | Carboxylic acid derivative compounds and drugs containing these compounds as active ingredient | СҰҩƷ��ҵ��ʽ���� | 2004-12-01 | — | — | CN | claimed |
| EP-1431267-A1 | CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-23 | — | — | EP | claimed |
| US-7786161-B2 | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| CN-101284773-A | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO (JP) | 2008-10-15 | — | — | CN | disclosed |
| US-20070167500-A1 | Remedy for urinary tract diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1642594-A1 | REMEDY FOR URINARY TRACT DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| CN-1551866-A | Carboxylic acid derivative compounds and drugs containing these compounds as active ingredient | СҰҩƷ��ҵ��ʽ���� | 2004-12-01 | — | — | CN | disclosed |
| EP-1431267-A1 | CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | PTGER2, PTGER4, PTGER1 | KMT2A 2549/4885MEN1 3705/4885KDM4E 3099/4885 |
| US-20070167500-A1 | Remedy for urinary tract diseases | PTGER3, PTGER1, PTGES3 | KMT2A 3004/4885MEN1 4455/4885KDM4E 3619/4885 |
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | PTGER2, PTGER4, PTGER1 | KMT2A 2400/4885MEN1 3489/4885KDM4E 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.